Literature DB >> 17914927

Mechanism-based concepts of size and maturity in pharmacokinetics.

B J Anderson1, N H G Holford.   

Abstract

Growth and development can be investigated using readily observable demographic factors such as weight and age. Size is the primary covariate and can be referenced to a 70-kg person with allometry using a coefficient of 0.75 for clearance and 1 for volume. The use of these coefficients is supported by fractal geometric concepts and observations from diverse areas in biology. Fat free mass (FFM) might be expected to do better than total body weight when there are wide variations in fat affecting body composition. Clearance pathways develop in the fetus before birth. The use of postnatal age as a descriptor of maturation is unsatisfactory because birth may occur prematurely; therefore postmenstrual age is a superior predictor of elimination function. A sigmoid E(max) model (Hill equation) describes gradual maturation of clearance in early life leading to a mature adult clearance achieved at a later age.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17914927     DOI: 10.1146/annurev.pharmtox.48.113006.094708

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  404 in total

1.  Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations.

Authors:  Jonathan Chambers; Madhu Page-Sharp; Sam Salman; John Dyer; Timothy M E Davis; Kevin T Batty; Laurens Manning
Journal:  Eur J Clin Pharmacol       Date:  2018-12-04       Impact factor: 2.953

2.  Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.

Authors:  Christelle Rodrigues; Catherine Chiron; Elisabeth Rey; Olivier Dulac; Emmanuelle Comets; Gérard Pons; Vincent Jullien
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

Review 3.  Vancomycin: a review of population pharmacokinetic analyses.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

4.  Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.

Authors:  Ying Hong; Kenneth G Kowalski; Jenny Zhang; Li Zhu; Mariaarantxa Horga; Richard Bertz; Marc Pfister; Amit Roy
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

5.  Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery.

Authors:  Tomoyuki Mizuno; Katja M Gist; Zhiqian Gao; Michael F Wempe; Jeffrey Alten; David S Cooper; Stuart L Goldstein; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

6.  Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.

Authors:  H Li; D E Mager; B M Sandmaier; D G Maloney; M J Bemer; J S McCune
Journal:  J Clin Pharmacol       Date:  2013-02-04       Impact factor: 3.126

7.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

8.  Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

Authors:  Melanie S Joy; Debbie S Gipson; Mary Dike; Leslie Powell; Amber Thompson; Suzanne Vento; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 8.237

9.  Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.

Authors:  Heather E Vezina; Richard C Brundage; Henry H Balfour
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

10.  Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety.

Authors:  David Ley; Ingrid Hansen-Pupp; Aimon Niklasson; Magnus Domellöf; Lena E Friberg; Jan Borg; Chatarina Löfqvist; Gunnel Hellgren; Lois E H Smith; Anna-Lena Hård; Ann Hellström
Journal:  Pediatr Res       Date:  2012-10-24       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.